Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

(2014) K G J Pollock et al.   BRITISH JOURNAL OF CANCER

Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: A cross-sectional observational study in Wales and Scotland (UK)

(2013) Ned Powell et al.   JOURNAL OF CLINICAL VIROLOGY

Achieving high and equitable coverage of adolescent HPV vaccine in Scotland

(2013) Katy Sinka et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

(2013) D. Mesher et al.   VACCINE

Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence

(2011) Johannes A. Bogaards et al.   EPIDEMIOLOGY

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

(2011) Ali Rowhani-Rahbar et al.   JOURNAL OF CLINICAL VIROLOGY

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines

(2010) K Cuschieri et al.   BRITISH JOURNAL OF CANCER

Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England

(2010) R Howell-Jones et al.   BRITISH JOURNAL OF CANCER

The risk of cervical cancer associated with specific types of human papillomavirus: A case-control study in a UK population

(2010) Ned G. Powell et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

A review of human carcinogens—Part B: biological agents

(2009) Véronique Bouvard et al.   LANCET ONCOLOGY

Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study

(2008) S Hibbitts et al.   BRITISH JOURNAL OF CANCER

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

(2008) F. Xavier Bosch et al.   VACCINE